# Patient Disease Trajectories in Baricitinib 2-mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs


Mark C. Genovese,<sup>1</sup> Michael Weinblatt,<sup>2</sup> Jianmin Wu,<sup>3</sup> Bochao Jia,<sup>3</sup> Amanda Quebe,<sup>3</sup> Luna Sun,<sup>3</sup> Yun-fei Chen,<sup>3</sup> Cameron Helt,<sup>3</sup> A. Kirstin Bacani,<sup>3</sup> Paulo Reis,<sup>3</sup> Janet Pope<sup>4</sup> <sup>1</sup>Stanford University Medical Center, Palo Alto, USA; <sup>2</sup>Brigham and Women's Hospital, Boston, USA; <sup>4</sup>St Joseph's Hospital, Western University, London, Canada

#### **KEY RESULTS** BACKGROUND Baricitinib, a selective Janus kinase 1 and 2 inhibitor, is approved in more than 60 countries for the treatment of moderately-to-severely active rheumatoid arthritis (RA) Group 1 (N=90, 51.7%) In the Phase 3 RA-BEACON (NCT01721044) trial, baricitinib 60 2-mg demonstrated clinical efficacy in patients with RA who were inadequate responders to biologic disease-modifying antirheumatic drugs (bDMARDs)<sup>1</sup> It is important to understand if 0 4 8 12 16 20 24 patients have different disease response patterns and how these patterns relate to baseline LDA (CDAI ≤10) Response Rate Over Time characteristics, clinical measures, and patient outcomes Group 1 (N=90, 51.7%) 100-**OBJECTIVES** To identify patients' response 60patterns after receiving baricitinib 2-mg over 24 weeks in RA-BEACON 20-To examine the associated baseline characteristics and clinical disease 12 16 20 24 measures within each response Groups 1 and 2 had a rapid rate of CDAI improvement

## **METHODS**

pattern group

#### Study Design, RA-BEACON



<sup>a</sup> Concomitant treatment with stable doses of csDMARDs, NSAIDs, analgesic agents, glucocorticoids (<10 mg of prednisone or the equivalent per day), or a combination of these drugs was permitted <sup>b</sup> At Week 16, patients whose tender and swollen joint counts at baseline were reduced by <20% at both Week 14 and Week 16 were given rescue treatment (baricitinib 4-mg daily)

#### Key Eligibility Criteria


- Adults with moderately to severely active RA
- $\geq 6$  tender joints of 68 joints examined
- ≥6 swollen joints of 66 joints examined
- High-sensitivity C-reactive protein  $\geq 3 \text{ mg/L}$
- Inadequate response or intolerance to ≥1 tumor necrosis factor inhibitor
- ≥8 weeks stable background conventional synthetic DMARD

# Patients were Classified Into 3 Subgroups by GMM Based on Their CDAI Response Patterns

Loess smooth mean trajectory of CDAI by group

**--**-CDAI=10

# Summary of CDAI Values for the 3 Groups Identified




Group 2

12 16 20 24

Analyses

Group 2 (N=29, 16.7%)

Group 3



Group 3 (N=55, 31.6%)

4 8 12 16 20 24

# Week Gro 12 24

<sup>a</sup> Based on the group mean change from baseline

- (66%, ΔCDAI -34)
- at Week 24

Group 1

60

40

20

Analysis Population (N=174) Patients in RA-BEACON who received baricitinib 2-mg **Growth Mixture Model<sup>a</sup> Used to Classify Patient Response Patterns** Patient response subgroups identified based on observed CDAI values from Week 0 to 24 **Disease Trajectory Subgroup Comparisons** Baseline characteristics Achievement of LDA (CDAI ≤10) Change over time in: – CDAI - SJC28 and TJC28 – Pain VAS – HAQ-DI

<sup>a</sup> A novel latent class mixed model used to classify the longitudinal disease patterns instead of predefining a clinical responder at a specific time point

## **Application of Growth Mixture Model (GMM)**<sup>2</sup>

- Analysis strategy: Different from a responder analysis defined at a certain time point (for example, Clinical Disease Activity Index [CDAI] low disease activity responder at Week 24)
- Analysis specifications:
  - Baricitinib 2-mg only
  - CDAI observed data from Week 0 to 24 or up to rescue
  - No data imputation after rescue or discontinuation
  - The number of subgroups can be determined based on a data-driven method (such as Bayesian information criterion)
  - Comparisons are descriptive
  - No formal statistical comparisons were made

oup	Mean (SD)	∆CDAI (%)ª
1	33.9 (9.0)	-
2	51.3 (8.1)	-
3	52.2 (11.0)	-
1	16.1 (7.5)	-17.8 (52.6)
2	35.0 (11.3)	-16.3 (31.7)
3	45.2 (10.5)	-7.0 (13.4)
1	12.0 (7.7)	-21.8 (64.4)
2	24.6 (9.9)	-26.7 (52.0)
3	43.4 (12.2)	-8.8 (17.0)
1	11.8 (9.4)	-22.1 (65.3)
2	17.3 (8.0)	-34.0 (66.3)
3	42.6 (10.6)	-9.6 (18.3)

Group 1 had the lowest baseline CDAI, achieved 53% improvement in group mean of CDAI at Week 4 (change from baseline, ΔCDAI -18), 64% improvement at Week 12 (ΔCDAI -22),

and maintained similar improvement through 24 weeks Group 2 had higher baseline CDAI than Group 1, achieved 32%

improvement in mean CDAI at Week 4 ( $\Delta$ CDAI -16) with greater improvement at Week 12 (52%, ΔCDAI -27) and Week 24

Group 3 had a baseline CDAI similar to Group 2, but had smaller improvement, achieving 18% improvement in CDAI ( $\Delta$ CDAI -10)


## **Basaling Characteristics**

	Group 1	Group 2	Group 3
	(N=90)	(N=29)	(N=55)
Age, years	54.1 (11.6)	59.9 (11.1)	54.2 (9.6)
Male, n (%)	19 (21.1)	6 (20.7)	12 (21.8)
BMI, kg/m²	31.0 (7.6)	31.4 (7.9)	30.2 (8.4)
RF positive, n (%)	69 (76.7)	22 (75.9)	37 (67.3)
ACPA positive, n (%)	66 (73.3)	23 (79.3)	35 (63.6)
hsCRP, mg/L	18.7 (22.3)	18.8 (18.6)	22.3 (24.7)
ESR, mm/h	40.8 (23.2)	43.8 (18.0)	51.4 (25.3)
Duration of RA, years	13.4 (7.5)	15.8 (8.5)	13.1 (8.6)
≥3 bDMARD use	23 (25.6)	7 (24.1)	20 (36.4)
TJC28	12.4 (5.2)	20.8 (3.8)	21.7 (5.5)
SJC28	8.9 (3.9)	16.3 (4.8)	16.0 (6.2)
PGA	62.0 (17.6)	69.9 (13.9)	73.4 (14.9)
PatGA	62.5 (20.5)	71.8 (14.1)	73.2 (17.7)
Pain VAS	57.2 (22.9)	64.9 (20.5)	69.5 (17.3)
HAQ-DI	1.5 (0.5)	1.7 (0.6)	2.0 (0.5)
DAS28-hsCRP	5.5 (0.7)	6.6 (0.6)	6.6 (0.8)

Data are mean (standard deviation) unless stated otherwise

Compared to Groups 1 and 2:

- Group 3 had numerically more pain and worse physical function (HAQ-DI) at baseline, and a larger proportion of patients who had used ≥3 bDMARDs
- Group 3 had a numerically lower proportion of ACPA positive or RF positive patients
- Groups 3 had numerically higher baseline ESR and CRP



The distributions of SJC28, TJC28, pain VAS, and HAQ-DI within each response pattern showed similar trajectories as the corresponding group CDAI trajectory


#### **ABBREVIATIONS**

ACPA=anti-citrullinated protein antibody; ACR20=American College of Rheumatology ≥20% response; bDMARD=biologic disease-modifying antirheumatic drugs; BMI=body mass index; CDAI=Clinical Disease Activity Index; csDMARD=conventional synthetic disease-modifying antirheumatic drug; DAS28=Disease Activity Score 28-joint count; ESR=erythrocyte sedimentation rate; GMM=growth mixture model; HAQ-DI=Health Assessment Questionnaire-Disability Index; hsCRP=high-sensitivity C-reactive protein; LDA=low disease activity; Loess=locally estimated scatterplot smoothing; NSAID=nonsteroidal anti-inflammatory drug; PatGA=Patient's Global Assessment of disease activity; PGA=Physician's Global Assessment of disease activity; QD=once daily; RA=rheumatoid arthritis; RF=rheumatoid factor; SD=standard deviation; SJC28=swollen joint count of 28 joints examined; TJC28=tender joint count of 28 joints examined; VAS=visual analog scale: W=Week

#### CONCLUSIONS

- There were 3 response patterns to baricitinib 2-mg treatment in the **RA-BEACON** trial
- The majority of baricitinib 2-mg-treated patients achieved a good response (Groups 1 and 2, 68%) with at least 50% improvement in CDAI by Week 12
- Response was observed as early as Week 4 and was maintained or continued to improve in these groups through Week 24
- Patients who were less responsive (Group 3) tended to be more treatment experienced with greater pain and worse physical function at baseline
- Strengths: Prospectively collected data with minimal missing information
- The data help us understand trajectories of response for baricitinib 2-mg
- Limitation: The generalizability of data collected from randomized clinical trials of patients with moderately to severely active and refractory RA to usual practice is unknown

## **Baricitinib 2-mg Patient Trajectory: CDAI Response Over Time (All Patients)**



#### DISCLOSURES

• M. C. Genovese has received grant/research support and is a consultant for: AbbVie, Eli Lilly and Company, Galapagos, and Pfizer; M. Weinblatt has been a consultant and/or has received research support from: AbbVie, Amgen, BMS, Corrona, Crescendo Bioscience, Eli Lilly and Company, Gilead, GlaxoSmithKline, Lycera, Merck, Novartis, Pfizer, Roche, Samsung, Sanofi/Regeneron, and SetPoint; J. Wu, B. Jia, A. Quebe, L. Sun, Y-F. Chen, C. Helt, A. K. Bacani, and P. Reis are employees and shareholders of Eli Lilly and Company; J. Pope has received research grants from: Bayer, BMS, Merck, Pfizer, Roche, and UCB, and received honoraria from: AbbVie, Actelion, Amgen, Bayer, BMS, Celtrion, Eli Lilly and Company, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, and UCB

This study was sponsored by Eli Lilly and Company, under license from Incyte Corporation. Medical writing assistance was provided by Samantha Forster, PhD, CMPP, of ProScribe – Envision Pharma Group, and was funded by Eli Lilly and Company

This study was and previously presented at American College of Rheumatology (ACR); Atlanta, USA; November 8-13, 2019

#### REFERENCES

1. Genovese MC, et al. N Engl J Med. 2016; 374:1243-1252. 2. Proust-Lima C, et al. J Stat Softw. 2016;78;doi:10.18637/jss.v078.i02.

